Home » Stocks » DBTX

Decibel Therapeutics, Inc. (DBTX)

Stock Price: $14.68 USD -2.99 (-16.92%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $14.92 +0.24 (1.64%) Mar 5, 5:07 PM
Market Cap 356.75M
Revenue (ttm) n/a
Net Income (ttm) -32.67M
Shares Out 24.28M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $14.68
Previous Close $17.67
Change ($) -2.99
Change (%) -16.92%
Day's Open 17.85
Day's Range 13.28 - 17.85
Day's Volume 261,771
52-Week Range 13.28 - 24.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at ...

GlobeNewsWire - 1 week ago

Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Rese...

Benzinga - 2 weeks ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented t...

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, MTEM, NEXI, ONCR, PRTA, TLIS
GlobeNewsWire - 2 weeks ago

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to resto...

GlobeNewswire - 3 weeks ago

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...

PharmTech - 1 month ago

Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.

GenomeWeb - 1 month ago

Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.

NASDAQ - 1 month ago

Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.

SEC - 1 month ago

Decibel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

The Hearing Journal - 2 months ago

...Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M.

Business Wire - 2 months ago

BOSTON--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announc...

About DBTX

Decibel Therapeutics, a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disor... [Read more...]

Industry
Biotechnology
IPO Date
Feb 12, 2021
CEO
Laurence Reid, Ph.D.
Employees
37
Stock Exchange
NASDAQ
Ticker Symbol
DBTX
Full Company Profile

Financial Performance

Financial Statements